$Neuronetics(STIM.US)$ NEWS New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital Neuronetics, Inc. (NASDAQ: STIM) announces significant clinical findings in Brain Stimulation journal regarding the predictive value of early symptom improvement in major depressive disorder (MDD) patients undergoing transcranial magnetic stimulation (TMS) treatment. Lack of early improvement does not predict final non-response status, emphasizing the importance of completing the full 36-...
Neuronetics' President's recent share selling, along with more insider selling than buying over the past year, doesn't inspire confidence. The lower insider ownership compared to most companies also raises concerns. No rush to buy Neuronetics' stock.
Despite Neuronetics' projected revenue growth outpacing its industry, its lower P/S indicates potential shareholder skepticism towards future forecasts. It suggests possible risks leading to future revenue volatility.
$Neuronetics(STIM.US)$reported record revenue of $17.9 million for Q3 2023, marking an 8% increase from the same period last year. The company also revised its full-year revenue guidance to between $70 million and $72 million.
Neuronetics股票討論區
NEWS
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics, Inc. (NASDAQ: STIM) announces significant clinical findings in Brain Stimulation journal regarding the predictive value of early symptom improvement in major depressive disorder (MDD) patients undergoing transcranial magnetic stimulation (TMS) treatment. Lack of early improvement does not predict final non-response status, emphasizing the importance of completing the full 36-...
Dow Jones· just
暫無評論